Loading...
Market
How will Sangamo Therapeutics' stock price change by August 6, 2025, post-Genentech deal?
2
Resolution / Starting Odds
Up by more than 50% • 25%
Up by 0% to 50% • 25%
Down by 0% to 50% • 25%
Down by more than 50% • 25%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Story
Sangamo and Genentech Partner on $50M Upfront, $1.9B Genomic Medicines Deal
Aug 6, 2024, 12:27 PM
Sangamo Therapeutics has announced a global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. The deal includes $50 million in near-term upfront license fees and milestone payments, with potential development and commercial milestone payments of up to $1.9 billion. The agreement involves the use of Sangamo's ZF-repressors and STAC-BBB AAV delivery systems targeting tau and another undisclosed neurodegenerative condition. The tau-repressor therapy was previously part of a 2020 partnership with Biogen. This partnership aims to advance the development of genomic medicines for conditions such as Alzheimer's disease. The cash-strapped Sangamo expects this deal to extend its runway.
View original story
Similar markets
Stock rises by more than 10% • 25%
Stock rises by 0-10% • 25%
Stock falls by 0-10% • 25%
Stock falls by more than 10% • 25%
Approved • 25%
Rejected • 25%
Request for more data • 25%
Other • 25%
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
Decrease or no change • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Above 50% increase • 25%
10% to 50% increase • 25%
0% to 10% increase • 25%
Decrease • 25%
Stock price above $50 • 25%
Stock price between $20 and $50 • 25%
Stock price between $5 and $20 • 25%
Stock price below $5 • 25%
Increase by more than 5% • 25%
Decrease by more than 5% • 25%
Fluctuate within ±5% • 25%
No significant change • 25%